Journal
CLINICAL AND VACCINE IMMUNOLOGY
Volume 21, Issue 5, Pages 783-786Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/CVI.00011-14
Keywords
-
Categories
Funding
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Ask authors/readers for more resources
Antivector immunity may limit the immunogenicity of adenovirus vector vaccines. We tested sera from individuals immunized with adenovirus type 4 and 7 (Ad4 and Ad7, respectively) vaccine or naturally infected with Ad4 for their ability to neutralize a panel of E1-deleted human and chimpanzee adenoviruses (ChAd). Small statistically significant increases in titers to ChAd63, ChAd3, human Ad35, and human Ad5 were observed. Neutralizing antibodies elicited by Ad4 infection or immunization results in a small amount of adenovirus cross-reactivity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available